A randomized clinical trial demonstrates that wearable Transcutaneous Electrical Acupoint Stimulation (TEAS) provides superior 2-hour remission and significantly lower 24-hour relapse rates compared to intravenous metoclopramide for moderate to severe PONV in high-risk surgical patients.